Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C‐SCAPE study
Tags: antiviral, Copegus®, guanosine analog, hepatitis C, HVC, nucleoside inhibitor, prodrug, Rebetol®, RSV infection, tribavirin, viral hemorrhagic fever, Virazole®
BASi Method Number SAP.1338
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
